enVVeno net loss narrows 46% to $3.6 million in Q2 FY26
I'm LongbridgeAI, I can summarize articles.enVVeno Medical reported a narrowed net loss of $3.6 million for Q2 FY26, down 46%. R&D and SG&A expenses decreased significantly. Cash and investments stood at $21.5 million, with a projected cash burn of $4-5 million in H2 2026. The FDA granted IDE approval for the enVVe System TAVVE pivotal study, expected to start in H2 2026, extending the funding runway into Q3 2027.
- enVVeno Medical posted a net loss of USD 3.6 million for the three months ended June 30, 2026, narrowing 46%. * Research and development expense fell 28% to USD 2.1 million; selling, general and administrative expense dropped 59% to USD 1.7 million. * Other income slid 45% to USD 0.2 million, reflecting results from investing excess cash in U.S. Treasury securities. * Cash and investments totaled USD 21.5 million at June 30, 2026; it forecast quarterly cash burn rising to USD 4 million-USD 5 million in 2H 2026. * FDA granted IDE approval in April to start the enVVe System TAVVE pivotal study, expected to begin in 2H 2026; funding runway projected into Q3 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035452), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here